Nephrology Genetics Panel
The Nephrology Genetics Panel is an advanced targeted Next-Generation Sequencing (NGS) assay designed to comprehensively profile germline mutations in genes responsible for renal structural integrity, glomerular filtration, tubular transport, and ciliopathy networks. Genetic factors account for a significant proportion of Chronic Kidney Disease (CKD) cases, particularly in pediatric populations and early-onset adult end-stage renal disease (ESRD). This panel resolves diagnostic ambiguity in cystic kidney diseases, glomerulopathies, tubulopathies, and syndromic renal disorders, providing actionable data for targeted therapy, kidney transplantation risk assessment, donor safety, and cascade family testing.
Key Features & Advantages
- Reduces the Need for Renal Biopsies: Offers a non-invasive diagnostic alternative or clarifies ambiguous histological findings (e.g., differentiating Alport Syndrome from Thin Basement Membrane Nephropathy).
- Informs Kidney Transplantation & Recurrence Risk: Identifying a genetic cause in conditions like Focal Segmental Glomerulosclerosis (FSGS) indicates a lower risk of post-transplant disease recurrence, safely guiding living-donor transplantation decisions.
- Ensures Living Donor Safety: Screens related potential living donors to prevent harvesting kidneys from asymptomatic carriers who may develop ESRD later in life.
- Prevents Unnecessary Immunosuppression: Avoids ineffective high-dose immunosuppressive therapies and toxicities in patients with monogenic forms of steroid-resistant nephrotic syndrome.
Nephrology NGS Panel vs. Conventional Renal Diagnostics
| FeatureNephrology Genetics Panel (NGS)Standard Renal Diagnostics (Serum Creatinine, eGFR, Renal Biopsy) | ||
| Diagnostic Scope | Genes encoding structural, transport, and ciliary proteins | Serum waste levels, filtration rate, and tissue histology |
| Etiological Resolution | High (Pinpoints the exact molecular defect) | Phenotypic (Shows renal damage, not the underlying cause) |
| Invasiveness & Risk | Non-invasive (Peripheral blood or saliva sample) | High (Biopsy risks include bleeding, pain, and hematoma) |
| Post-Transplant Recurrence Prediction | High (Differentiates genetic FSGS from autoimmune forms) | Low (Monitors graft function post-surgery without predictive power) |
| Donor Carrier Screening | Absolute (Identifies subclinical genetic risks in related donors) | Limited (May miss asymptomatic early-stage genetic traits) |
Key Applications
- Cystic Kidney Diseases: Comprehensive screening for Autosomal Dominant/Recessive Polycystic Kidney Disease (PKD1, PKD2, PKHD1) and Nephronophthisis.
- Glomerular Diseases & Podocytopathies: Profiling Alport Syndrome (COL4A3, COL4A4, COL4A5), Steroid-Resistant Nephrotic Syndrome (SRNS), and FSGS.
- Tubulopathies & Electrolyte Imbalances: Genetic evaluation of Bartter, Gitelman, Liddle syndromes, and Renal Tubular Acidosis (RTA).
- Renal Ciliopathies & Thrombotic Microangiopathies: Screening for Bardet-Biedl Syndrome, Joubert Syndrome, and Atypical Hemolytic Uremic Syndrome (aHUS - CFH, C3, CD46).
The Nucleus Genetics Advantage: Combining broad target NGS panels aligned with KDIGO guidelines, deep sequence coverage, and expert curation by medical geneticists and nephrologists, we convert complex genomic data into precise, life-saving clinical insights.
Get Information About This Service
Our expert team is ready to answer your questions and offer tailored solutions.
Contact Form →